<p>根據 Janus Henderson Group PLC 最近向證券交易委員會提交的文件，該公司在 2023 年第四季度增持了 Catalyst Pharmaceuticals, Inc.（NASDAQ:CPRX - 免費報告）的股份，增幅為 32.2%。該基金在本季度額外購買了 115,832 股後，持有 476,023 股這家生物製藥公司的股票。在最近的報告期結束時，Janus Henderson Group PLC 持有 Catalyst Pharmaceuticals 的股份佔比為 0.40%，價值 9,935,000 美元。</p>
<ul>
<li>2 家生物科技公司憑藉單一產品在市場上引起轟動</li>
</ul>
<p>其他一些機構投資者最近也買賣了 CPRX 的股票。Farther Finance Advisors LLC 在第四季度將其在 Catalyst Pharmaceuticals 的股份增加了 125.1%。Farther Finance Advisors LLC 現在持有 2,690 股這家生物製藥公司的股票，價值 56,000 美元，此前在該期間額外購買了 1,495 股。Allspring Global Investments Holdings LLC 在第四季度將其在 Catalyst Pharmaceuticals 的股份增加了 13.9%。Allspring Global Investments Holdings LLC 現在持有 417,332 股這家生物製藥公司的股票，價值 8,710,000 美元，此前在該期間額外收購了 50,888 股。Spire Wealth Management 在第四季度將其在 Catalyst Pharmaceuticals 的股份增加了 1,342.9%。Spire Wealth Management 現在持有 14,429 股這家生物製藥公司的股票，價值 301,000 美元，此前在上個季度額外購買了 13,429 股。Sanctuary Advisors LLC 在第四季度將其在 Catalyst Pharmaceuticals 的股份增加了 91.5%。Sanctuary Advisors LLC 現在持有 59,447 股這家生物製藥公司的股票，價值 1,241,000 美元，此前在上個季度額外購買了 28,407 股。最後，Nilsine Partners LLC 在第四季度收購了 Catalyst Pharmaceuticals 的新股份，價值 700,000 美元。79.22% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>分析師設定新目標價</h2>
<p>幾家券商最近對 CPRX 進行了評估。StockNews.com 在 2 月 28 日的研究報告中將 Catalyst Pharmaceuticals 的股票評級從 “買入” 上調至 “強力買入”。HC Wainwright 在 2 月 28 日的研究報告中重申了 “買入” 評級，並設定了 35.00 美元的目標價。Stephens 在 2 月 27 日的研究報告中重申了 “增持” 評級，並設定了 33.00 美元的目標價。Baird R W 在 2 月 3 日的報告中將 Catalyst Pharmaceuticals 的評級上調至 “強力買入”。最後，Robert W. Baird 在 3 月 3 日的報告中將 Catalyst Pharmaceuticals 的目標價從 28.00 美元提高至 32.00 美元，並給予該公司 “跑贏大盤” 的評級。七位股票研究分析師對該股票給予了買入評級，兩位給予了強力買入評級。根據 MarketBeat 的數據，Catalyst Pharmaceuticals 目前的共識評級為 “買入”，平均目標價為 32.29 美元。</p>
<ul>
<li>小型股 Catalyst Pharma 是市場上表現最佳的股票之一</li>
</ul>
<p><strong>查看我們對 CPRX 的最新分析</strong></p>
<h2>Catalyst Pharmaceuticals 的價格表現</h2>
<p>Catalyst Pharmaceuticals 的股票在週五開盤價為 24.37 美元。Catalyst Pharmaceuticals, Inc.的 12 個月低點為 14.75 美元，12 個月高點為 26.16 美元。該公司的 50 日簡單移動平均線為 23.23 美元，200 日簡單移動平均線為 22.47 美元。該股票的市值為 29.7 億美元，市盈率為 20.65，市盈增長比率為 3.31，貝塔值為 0.70。</p>
<h2>Catalyst Pharmaceuticals 的內部交易</h2>
<p>在 Catalyst Pharmaceuticals 的其他新聞中，內部人士 Gary Ingenito 在 3 月 5 日的交易中出售了 44,904 股股票。該股票的平均售價為 22.09 美元，總價值為 991,929.36 美元。交易完成後，內部人士現在持有 68,873 股該公司的股票，價值約為 1,521,404.57 美元。這代表了他們持股比例的 39.47% 的下降。該交易已在 SEC 的法律文件中披露，可以通過此鏈接訪問。此外，內部人士 Brian Elsbernd 在 3 月 3 日的交易中出售了 62,975 股股票。該股票的平均售價為 22.98 美元，總價值為 1,447,165.50 美元。交易完成後，內部人士現在持有 188,564 股該公司的股票，價值 4,333,200.72 美元。該交易使其持股比例下降了 25.04%。該銷售的披露信息可以在這裏找到。過去 90 天內，內部人士共出售了 351,879 股公司股票，價值 8,214,815 美元。當前 10.40% 的股票由內部人士持有。</p>
<h2>Catalyst Pharmaceuticals 公司簡介</h2>
<p>（免費報告）</p>
<p>Catalyst Pharmaceuticals, Inc.是一家商業階段的生物製藥公司，專注於開發和商業化針對美國罕見的、嚴重的、慢性神經肌肉和神經疾病的治療方案。它提供 Firdapse，一種用於治療拉姆伯特 - 伊頓肌無力綜合症（LEMS）患者的氨法普利磷酸鹽片；以及 Ruzurgi，用於治療兒童 LEMS 患者。</p>
<h2>進一步閲讀</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Catalyst Pharmaceuticals</li>
<li>如何計算通貨膨脹率</li>
<li>Meta 的 AI 增長五大關鍵支柱——扎克伯格的大膽願景</li>
<li>如何有效使用 MarketBeat 評級篩選器</li>
<li>零售投資者在 Rocket Lab 上大舉下注——你也應該這樣做嗎？</li>
<li>我在哪裏可以找到 52 周的高點和低點？</li>
<li>GE 航空：卡塔爾交易推動數十億美元的增長引擎</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1BSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1BSWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Catalyst Pharmaceuticals 嗎？</h2>
<p>在考慮 Catalyst Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Catalyst Pharmaceuticals 並不在名單上。</p>
<p>雖然 Catalyst Pharmaceuticals 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

觸媒制藥公司

<p>Janus Henderson Group PLC 在第四季度將其在 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) 的持股增加了 32.2%，目前擁有 476,023 股，價值約 990 萬美元。其他機構投資者也增加了他們的持股。分析師對 Catalyst Pharmaceuticals 的一致評級為 “買入”，平均目標價為 32.29 美元。該股票開盤價為 24.37 美元，12 個月的價格區間為 14.75 美元至 26.16 美元。最近的內部交易包括高管的大量股票出售</p>

<p>Janus Henderson Group PLC boosted its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 32.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 476,023 shares of the biopharmaceutical company's stock after buying an additional 115,832 shares during the quarter. Janus Henderson Group PLC owned 0.40% of Catalyst Pharmaceuticals worth $9,935,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>根據 Janus Henderson Group PLC 最近向證券交易委員會提交的文件，該公司在 2023 年第四季度增持了 Catalyst Pharmaceuticals, Inc.（NASDAQ:CPRX - 免費報告）的股份，增幅為 32.2%。該基金在本季度額外購買了 115,832 股後，持有 476,023 股這家生物製藥公司的股票。在最近的報告期結束時，Janus Henderson Group PLC 持有 Catalyst Pharmaceuticals 的股份佔比為 0.40%，價值 9,935,000 美元。</p>
</div><ul>
<li>2 Biotechs Making Waves With A Single Product in their Pipeline</li>
</ul>
<div class="lb-trans"><ul>
<li>2 家生物科技公司憑藉單一產品在市場上引起轟動</li>
</ul>
</div><p>A number of other institutional investors also recently bought and sold shares of CPRX. Farther Finance Advisors LLC grew its stake in shares of Catalyst Pharmaceuticals by 125.1% during the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after purchasing an additional 1,495 shares during the period. Allspring Global Investments Holdings LLC grew its stake in Catalyst Pharmaceuticals by 13.9% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 417,332 shares of the biopharmaceutical company's stock valued at $8,710,000 after acquiring an additional 50,888 shares during the period. Spire Wealth Management boosted its stake in Catalyst Pharmaceuticals by 1,342.9% during the 4th quarter. Spire Wealth Management now owns 14,429 shares of the biopharmaceutical company's stock worth $301,000 after purchasing an additional 13,429 shares during the last quarter. Sanctuary Advisors LLC boosted its stake in Catalyst Pharmaceuticals by 91.5% during the 4th quarter. Sanctuary Advisors LLC now owns 59,447 shares of the biopharmaceutical company's stock worth $1,241,000 after purchasing an additional 28,407 shares during the last quarter. Finally, Nilsine Partners LLC acquired a new stake in Catalyst Pharmaceuticals during the 4th quarter worth $700,000. 79.22% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他一些機構投資者最近也買賣了 CPRX 的股票。Farther Finance Advisors LLC 在第四季度將其在 Catalyst Pharmaceuticals 的股份增加了 125.1%。Farther Finance Advisors LLC 現在持有 2,690 股這家生物製藥公司的股票，價值 56,000 美元，此前在該期間額外購買了 1,495 股。Allspring Global Investments Holdings LLC 在第四季度將其在 Catalyst Pharmaceuticals 的股份增加了 13.9%。Allspring Global Investments Holdings LLC 現在持有 417,332 股這家生物製藥公司的股票，價值 8,710,000 美元，此前在該期間額外收購了 50,888 股。Spire Wealth Management 在第四季度將其在 Catalyst Pharmaceuticals 的股份增加了 1,342.9%。Spire Wealth Management 現在持有 14,429 股這家生物製藥公司的股票，價值 301,000 美元，此前在上個季度額外購買了 13,429 股。Sanctuary Advisors LLC 在第四季度將其在 Catalyst Pharmaceuticals 的股份增加了 91.5%。Sanctuary Advisors LLC 現在持有 59,447 股這家生物製藥公司的股票，價值 1,241,000 美元，此前在上個季度額外購買了 28,407 股。最後，Nilsine Partners LLC 在第四季度收購了 Catalyst Pharmaceuticals 的新股份，價值 700,000 美元。79.22% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>Several brokerages have recently weighed in on CPRX. StockNews.com raised shares of Catalyst Pharmaceuticals from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Friday, February 28th. HC Wainwright reissued a &#34;buy&#34; rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Stephens reissued an &#34;overweight&#34; rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Baird R W raised Catalyst Pharmaceuticals to a &#34;strong-buy&#34; rating in a report on Monday, February 3rd. Finally, Robert W. Baird increased their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an &#34;outperform&#34; rating in a report on Monday, March 3rd. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, Catalyst Pharmaceuticals presently has a consensus rating of &#34;Buy&#34; and an average target price of $32.29.</p>
<div class="lb-trans"><p>幾家券商最近對 CPRX 進行了評估。StockNews.com 在 2 月 28 日的研究報告中將 Catalyst Pharmaceuticals 的股票評級從 “買入” 上調至 “強力買入”。HC Wainwright 在 2 月 28 日的研究報告中重申了 “買入” 評級，並設定了 35.00 美元的目標價。Stephens 在 2 月 27 日的研究報告中重申了 “增持” 評級，並設定了 33.00 美元的目標價。Baird R W 在 2 月 3 日的報告中將 Catalyst Pharmaceuticals 的評級上調至 “強力買入”。最後，Robert W. Baird 在 3 月 3 日的報告中將 Catalyst Pharmaceuticals 的目標價從 28.00 美元提高至 32.00 美元，並給予該公司 “跑贏大盤” 的評級。七位股票研究分析師對該股票給予了買入評級，兩位給予了強力買入評級。根據 MarketBeat 的數據，Catalyst Pharmaceuticals 目前的共識評級為 “買入”，平均目標價為 32.29 美元。</p>
</div><ul>
<li>Small-Cap Catalyst Pharma Is Among Market's Best Price Performers</li>
</ul>
<div class="lb-trans"><ul>
<li>小型股 Catalyst Pharma 是市場上表現最佳的股票之一</li>
</ul>
</div><p><strong>View Our Latest Analysis on CPRX</strong></p>
<div class="lb-trans"><p><strong>查看我們對 CPRX 的最新分析</strong></p>
</div><h2>Catalyst Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Catalyst Pharmaceuticals 的價格表現</h2>
</div><p>Catalyst Pharmaceuticals stock opened at $24.37 on Friday. Catalyst Pharmaceuticals, Inc. has a 12 month low of $14.75 and a 12 month high of $26.16. The business has a 50 day simple moving average of $23.23 and a 200-day simple moving average of $22.47. The stock has a market capitalization of $2.97 billion, a PE ratio of 20.65, a price-to-earnings-growth ratio of 3.31 and a beta of 0.70.</p>
<div class="lb-trans"><p>Catalyst Pharmaceuticals 的股票在週五開盤價為 24.37 美元。Catalyst Pharmaceuticals, Inc.的 12 個月低點為 14.75 美元，12 個月高點為 26.16 美元。該公司的 50 日簡單移動平均線為 23.23 美元，200 日簡單移動平均線為 22.47 美元。該股票的市值為 29.7 億美元，市盈率為 20.65，市盈增長比率為 3.31，貝塔值為 0.70。</p>
</div><h2>Insider Transactions at Catalyst Pharmaceuticals</h2>
<div class="lb-trans"><h2>Catalyst Pharmaceuticals 的內部交易</h2>
</div><p>In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,904 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the transaction, the insider now owns 68,873 shares in the company, valued at approximately $1,521,404.57. This represents a 39.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Brian Elsbernd sold 62,975 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the transaction, the insider now owns 188,564 shares of the company's stock, valued at $4,333,200.72. The trade was a 25.04% decrease in their position. The disclosure for this sale can be found here. Insiders sold 351,879 shares of company stock worth $8,214,815 over the last 90 days. 10.40% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在 Catalyst Pharmaceuticals 的其他新聞中，內部人士 Gary Ingenito 在 3 月 5 日的交易中出售了 44,904 股股票。該股票的平均售價為 22.09 美元，總價值為 991,929.36 美元。交易完成後，內部人士現在持有 68,873 股該公司的股票，價值約為 1,521,404.57 美元。這代表了他們持股比例的 39.47% 的下降。該交易已在 SEC 的法律文件中披露，可以通過此鏈接訪問。此外，內部人士 Brian Elsbernd 在 3 月 3 日的交易中出售了 62,975 股股票。該股票的平均售價為 22.98 美元，總價值為 1,447,165.50 美元。交易完成後，內部人士現在持有 188,564 股該公司的股票，價值 4,333,200.72 美元。該交易使其持股比例下降了 25.04%。該銷售的披露信息可以在這裏找到。過去 90 天內，內部人士共出售了 351,879 股公司股票，價值 8,214,815 美元。當前 10.40% 的股票由內部人士持有。</p>
</div><h2>Catalyst Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Catalyst Pharmaceuticals 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.</p>
<div class="lb-trans"><p>Catalyst Pharmaceuticals, Inc.是一家商業階段的生物製藥公司，專注於開發和商業化針對美國罕見的、嚴重的、慢性神經肌肉和神經疾病的治療方案。它提供 Firdapse，一種用於治療拉姆伯特 - 伊頓肌無力綜合症（LEMS）患者的氨法普利磷酸鹽片；以及 Ruzurgi，用於治療兒童 LEMS 患者。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Catalyst Pharmaceuticals</li>
<li>How to Calculate Inflation Rate</li>
<li>Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision</li>
<li>How to Effectively Use the MarketBeat Ratings Screener</li>
<li>Retail Investors Are Betting Big on Rocket Lab—Should You Too?</li>
<li>Where Do I Find 52-Week Highs and Lows?</li>
<li>GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Catalyst Pharmaceuticals</li>
<li>如何計算通貨膨脹率</li>
<li>Meta 的 AI 增長五大關鍵支柱——扎克伯格的大膽願景</li>
<li>如何有效使用 MarketBeat 評級篩選器</li>
<li>零售投資者在 Rocket Lab 上大舉下注——你也應該這樣做嗎？</li>
<li>我在哪裏可以找到 52 周的高點和低點？</li>
<li>GE 航空：卡塔爾交易推動數十億美元的增長引擎</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1BSWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=CPRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Catalyst Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Catalyst Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Catalyst Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Catalyst Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Catalyst Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Catalyst Pharmaceuticals 並不在名單上。</p>
</div><p>While Catalyst Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Catalyst Pharmaceuticals 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Janus Henderson 集團 PLC 增加了其在觸媒製藥公司（NASDAQ:CPRX）的股份